by Melissa Rohman, Northwestern University Credit: Unsplash/CC0 Public Domain Patients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent response and relapse-free survival, according to a recent clinical trial published in Blood. The results suggest that vemurafenib is an effective second-line treatment option for these patients. “This finding is important because...
